TIDMAREC

RNS Number : 0205S

Arecor Therapeutics PLC

11 November 2021

Arecor Therapeutics plc

("Arecor" or the "Group")

ARECOR GRANTED KEY CANADIAN PATENT FOR PROPRIETARY TECHNOLOGY ENABLING HIGHLY CONCENTRATED BIOTHERAPEUTICS

Cambridge, UK, 11 November 2021. Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives, continues to build a strong patent portfolio protecting its proprietary Arestat(TM) technology. Arecor is pleased to announce that the Canadian Intellectual Property Office has granted a key patent, CA2861402, with claims protecting a specific part of the technology used in the development of stable, low-viscosity formulations of highly concentrated protein therapeutics, including monoclonal antibodies, fusion proteins and more complex protein constructs.

Dr Jan Jezek, Chief Scientific Officer at Arecor, commented : "The recently granted Canadian patent is an important milestone in our rapidly growing patent portfolio. We have been very successful in patenting unique combinations of excipients that improve considerably critical quality attributes of protein and peptide-based therapeutics, enabling their convenient delivery. This new patent relates specifically to concentrated protein formulations, which is one of the most challenging areas of the biopharmaceutical drug delivery. It strengthens our IP portfolio and our position as a world leader in the formulation of superior biotherapeutics and vaccines."

The Group's Arestat(TM) technology enables superior product profiles across a broad range of therapies, including various types of biopharmaceuticals, specialty hospital products as well as vaccine compositions with improved stability. Arecor partners with leading pharmaceutical and biotechnology companies to deliver enhanced formulations of their therapeutic products under a technology licensing model, as well as developing an internal portfolio of proprietary products in diabetes and other indications.

A combination of high therapeutic dose and the highly desirable low injection volume often leads to a need for very highly concentrated formulations of protein therapeutics. Achieving such concentrated formulations can be exceptionally challenging. The granted Canadian patent provides Arecor's proprietary technology with broad protection in the formulation of highly concentrated compositions of therapeutic proteins, enabling convenient subcutaneous delivery of high value products to a higher specification compared with other approaches. It adds to patents already issued from the same patent family by Patent Offices in Europe, the US and India.

Arecor has invested in building a strong patent portfolio to protect the Arestat(TM) technology platform. The Group's intellectual property portfolio currently comprises 33 patent families, including >50 granted patents in Europe in the US and in other key territories.

-ENDS-

For more information, please contact:

 
 Arecor Therapeutics plc                    www.arecor.com 
 Dr Sarah Howell, Chief Executive Officer   Tel: +44 (0) 1223 426060 
                                             Email: info@arecor.com 
 
 Susan Lowther, Chief Financial Officer     Tel: +44 (0) 1223 426060 
                                             Email: info@arecor.com 
 
 Mo Noonan, Communications                  Tel: +44 (0) 7876 444977 
                                             Email: mo.noonan@arecor.com 
 
 Panmure Gordon (UK) Limited (NOMAD         Tel: +44 (0) 20 7886 2500 
  and Broker) 
  Freddy Crossley, Emma Earl (Corporate 
  Finance) 
  Rupert Dearden (Corporate Broking) 
 
 Consilium Strategic Communications 
 Chris Gardner, David Daley, Angela         Tel: +44 (0) 20 3709 5700 
  Gray                                       Email: arecor@consilium-comms.com 
 

Notes to Editors

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary formulation technology platform, Arestat(TM) , we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver enhanced formulations of their therapeutic products. The Arestat (TM) platform is supported by an extensive patent portfolio .

For further details please see our website, www.arecor.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCFBLLFFFLLFBD

(END) Dow Jones Newswires

November 11, 2021 02:00 ET (07:00 GMT)

Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Dec 2021 to Jan 2022 Click Here for more Arecor Therapeutics Charts.
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Jan 2021 to Jan 2022 Click Here for more Arecor Therapeutics Charts.